Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA should begin safety and efficacy reviews for all DESI drugs, HRG urges.

Executive Summary

FDA SHOULD CONDUCT SAFETY, EFFICACY REVIEW OF ALL DESI DRUGS, HRG maintains, beginning with the "most heavily prescribed drugs," the consumer advocate group urges in a May 29 letter to the agency. "Hundreds of millions of consumer dollars a year are at stake," Public Citizen's Health Research Group asserts in the letter, referring to brand name pharmaceuticals marketed prior to 1938.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel